Imeglimin-A New Oral Antidiabetic Agent in the Armamentarium of Resistant type2 Diabetics Specifically Regarding t2d with Correlated Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-A Minireview

AbstractImeglimin delineates an innovative oral glucose- diminishing agent that possesses a tetrahydrotriazine structure, which in the beginning got recommended in Japan in September2021. Despite both effectiveness in addition to safety of imeglimin in Japanese persons with T2D at the dosage of 1000 mg twice /day got illustrated in phase 3 clinical trials, the Trials ofImeglimin for Efficacy and Safety (TIMES 1–3), it has not been picked up further for evaluation in either United States of America(USA) or European countries ,the former despite certain catastrophies with Ozempic are further trying to launch the other GLP1A-however no attempt has been made to pursue imeglimin despite its structural akinness to metformin-the firstline oral antidiabetic medicine s theexposition which is beyond my comprehension other than pharmaceutical companies dictating the outcomes in this materialistic world.Here we further emphasize why investigators need to pursue scientific research in variable ethnicities to corroborate their efficacy throughout geographical regions scientifically without any bias to accept it as the oral agent when needed in view of it not having the inimical sequelae of metformin-the firstline oral antidiabetic medicine namely lactic acidosis, as well as considerably lesser gastrointestinal(GI) sequelae. Key Words; Imeglimin; oral antidiabetic medicine; metformin; gastrointestinal sequelae.